1 / 30

HAART: Where we’ve come, and where we’re going

HAART: Where we’ve come, and where we’re going. Jeffrey B. Greene, MD Chairperson- MCCC AIDS Institute. H.A.A.R.T. H ighly A ctive A nti- R etroviral T herapy. 1994-5: The HAART stage was set. Concorde Study ACTG studies of dual nucleosides

varden
Télécharger la présentation

HAART: Where we’ve come, and where we’re going

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HAART: Where we’ve come, and where we’re going Jeffrey B. Greene, MD Chairperson- MCCC AIDS Institute

  2. H.A.A.R.T. Highly Active Anti- Retroviral Therapy

  3. 1994-5: The HAART stage was set • Concorde Study • ACTG studies of dual nucleosides • Availability of reliable tests of viral load • Link between viral resistance and success of therapy • Saquinavir- 1st of a new class of antiviral

  4. The Birth of HIV/AIDS Therapeutics

  5. Short-term Clinical Effects of HAART • Resolution of HIV-induced symptoms • Marked reduction of HIV load in plasma • Increase in CD-4 cell counts • Control of active O.I.’s (e.g.: MAC, CMV) • Reduction in the incidence of new O.I.’s • Reduction of hospital days, and need for home IV therapies/ nutrition • 50% reduction in mortality rate in NY

  6. Change in the treatment paradigm The success of therapy was assessed by laboratory outcomes, instead of clinical outcomes

  7. TREAT HARD ! TREAT EARLY!

  8. It’s the Virus, STUPID! • Frequent alterations of regimen to address “bumps” in viral load • Increasing doses of antiviral agents • Adding pharmacologic enhancers to increase blood levels of antivirals (e.g.- Indinivir + Ritonivir) • “Mega-HAART”

  9. Keeping the Goals of Therapy in Focus Successful Treatment/ At the Expense of the Patient?

  10. Limitations of Aggressive HAART • Pill burden • Food and storage restrictions • Drug- drug interactions • Severe side-effects • Reduction in Quality of Life measures • Emergence of multiple drug resistance mutations

  11. Optimal HAART Requires Optimal Adherence • Understand patient-specific issues • Deal with patient concerns • Weigh efficacy against toxicity • Build a trusting provider/ patient relationship

  12. Defining “Optimal” Adherence • 95% accuracy in dosing • e.g.- missing no more than 3/ 60 doses/ month in a b.i.d. regimen • Respecting dietary restrictions • Proper storage of medication • Avoiding co-therapies that might alter the HAART blood levels

  13. Helping Patients Juggle The Therapies • Trusting provider relationships • Ongoing patient education • Utilize entire support team • Simply regimens • Dosing reminders (pill boxes, alarms, beepers)

  14. Helping Providers Juggle the Therapies • Know what therapeut-ic response to expect • Anticipate toxicity and monitor for it • Set reasonable treat-ment goals for patient • Understand and consider drug-drug interactions

  15. ABBOTT Labs Effect of Lopinivir on Viramune- None Effect of Viramune on Lopinivir- Negligible Recommendation: No change in recommended doses Boheringer-Ingleheim Effect of Lopinivir on Viramune- None Effect of Viramune on Lopinivir- 25% reduction in levels Recommendation: Increase dose of Lopinivir Lopinivir(Kaletra™) + Neviripine (Viramune ™)

  16. Resist the urge to try the “Drug-de-Jour”

  17. Long term toxicity of HAART • Hypercholesterolemia, Hypertriglyceridemia • Diabetes mellitis • Atherosclerotic cardiovascular and cerebrovascular disease • Lipodystrophy, fat- redistribution • Lipoatrophy • Lactic acidosis • Osteoporosis

  18. Then (1998) HIV symptoms CD-4 counts < 500 HIV-1/PCR > 10K Now (2001) HIV symptoms CD-4 counts < 350 HIV-1/PCR > 20-30K Initiating HAART

  19. Reasons for changing successful HAART • Drug Toxicity (e.g.- neuropathy, pancreatitis, renal stones, diarrhea/ nausea, insomnia/ neuroirritability, lipoatrophy, fat redistribution, diabetes, lipid abnormalities) • Quality of Life issues (e.g.- conflict of schedules, privacy, refrigeration) • Fear of long-term adverse drug reactions

  20. Definition of Failing HAART • Incompatible with proper adherence • Less than a 1.5- 2.5 log drop in viral load • Rising viral load after an initial drop • Falling CD-4 counts • ? CD-4 counts that do not increase from baseline? • Continued HIV-associated symptoms

  21. Factors Favoring Mutational Drug Resistance • Rapid rate of spontaneous mutation • Low therapeutic margins of many drugs • Erratic pharmacokinetics • Cross- resistance within classes • Providers with low index of suspicion • Prior exposure to sub-optimal therapy • Long duration of HAART • Poor adherence

  22. DNA R-T Enzyme R-T Enzyme RNA RNA

  23. Tests of HIV drug resistance • Genotypic Assays • Benefits: cheaper, quicker, may detect the emergence of resistance earlier. • Draw backs: Predictive, not demonstrative • Phenotypic Assays • Benefits: Useful in highly HAART-experienced patients needing salvage, may be able to semi-quantitate resistance • Drawbacks: Long turn-around, expensive

  24. Roles of HIV-Resistance Testing • Assessment of susceptibility prior to changing HAART; • Starting therapy in a previously treated patient • Changing successful therapy (PCR > 1-2,000) • Changing a failing regimen • ? Use in choosing an initial HAART regimen in treatment naïve patients • ? Use in choosing PEP

  25. Reasons for Interruption of HAART • Patient Fatigue, lack of confidence in rx., fear of toxicity, travel • Surgical or medical conditions requiring npo • A failing regimen, while resistance studies are pending • Poor adherence and need for further patient education

  26. Strategic/Structured Treatment Interruption(STI)- Rationale • ? Enhanced HIV-specific cellular and humoral immune response? • ? Reduction of long term toxicity?

  27. Possible Effects of HAART-induced long-term survival • Neurological (e.g.- neuropathy, dementia, neuromuscular) • Neoplastic • Skeletal/ Joint • Cardiovascular (e.g.- ASHD, ASPVD, cardiomyopathy) • Endocrinologic (e.g.- thyroid, hypothalamic, adrenal)

  28. New Directions in HAART • “User Friendly” drugs- (e.g.- QD/ BID, reduced toxicity, fewer drug-drug interactions) • Optimize pharmacodynamics of existing drugs • Develop NRTI, NNRTI, PI’s with improved resistance pattern • New Classes of drugs (e.g.- Fusion inhibitors, Chemokine antagonists, integrase inhibitors, TAT protein and CD-4 antagonists, vaccines, immunostimulants)

  29. Selected HIV agents in development • Nucleosides- DAPD, Tenofovir, Emtricitabine(FTC), DOTC, GW-42086, D-D4FC • Non-nucleosides- DPC 961, DPC 083, Capravirine, Calanolide A, TMC 120 • PI’s- Tipranavir, BMS 232632, AG 1776, DMP 450, CGP61755, DPC 681, DPC 684, TMC 126

  30. Selected HIV agents in development-con’t • Fusion Inhibitors- T-20, T- 1249 • Interleukin-2 • Vaccine development- vCP1452, gp-160 • Integrase Inhibitors- DCQA/DCTA, Zintevir • Hydroxyurea-like Compds- BCX-34, mycophenolate mofetil

More Related